Author: Dr. Ahmed M. Abdelsalam is an Associate Professor of General and Laparoscopic Surgery and the founder
Obesity treatment is evolving beyond surgery. Emerging anti-obesity medications like semaglutide and tirzepatide offer significant weight loss, challenging bariatric surgery’s dominance. While surgery remains superior in long-term outcomes, an integrated, personalised approach combining pharmacotherapy and surgery may redefine care. Strategic synergy, not replacement, is key to optimal patient outcomes.
Introduction
Obesity is no longer a lifestyle issue—it is a chronic, relapsing, multifactorial disease with major global health consequences. It affects over 650 million adults worldwide, contributing to rising rates of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), and various cancers. The mainstay of treatment traditionally revolved around behavioral modification, dietary changes, and exercise. However, these measures alone often prove inadequate due to biological resistance to weight loss.
More: https://www.asianhhm.com/articles/redefining-obesity-treatment-integrating-pharmacotherapy-and-surgery
Redefining Obesity Treatment: Integrating Pharmacotherapy and Surgery in the Modern Era